Publications by authors named "Takahide Okita"
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy is the first-choice treatment for neovascular age-related macular degeneration (nvAMD); however, patients often are burdened physically, financially, and mentally. We investigated the relationship between mental status and feasibility of an intravitreal ranibizumab treat-and-extend (TAE) regimen for nvAMD.
Methods: In this prospective, multicenter study, 75 patients with nvAMD received ranibizumab intravitreally in a TAE regimen.
Background: To evaluate the safety and efficacy of a new toric intraocular lens (IOL) with anchor-wing haptics.
Methods: The new toric IOL with anchor-wing haptics (NS60YT, NIDEK Co., Ltd.
[Evaluation of the efficacy of intravitreal gas injection for submacular hemorrhages].
Nippon Ganka Gakkai Zasshi
April 2008
Article Synopsis
- The study assessed the effectiveness of intravitreal gas injection for treating submacular hemorrhages (SMH) in 29 patients.
- Results showed that within five days of treatment, most patients experienced movement of the hemorrhage, and 79% achieved improved visual acuity after six months.
- The procedure often reduced the need for vitrectomy and had no serious complications, making it a viable first-choice treatment option for SMH.
[Influence of vitrectomy for diabetic retinopathy on health-related quality of life].
Nippon Ganka Gakkai Zasshi
February 2008
Article Synopsis
- The study aimed to assess the quality of life related to vision in patients who had vitrectomy for diabetic retinopathy, utilizing the Japanese version of the NEI VFQ-25 questionnaire.
- It involved 87 patients, with data collected one month before and six months after the surgery, and compared the results by different eye conditions.
- Results showed significant improvements in nearly all quality of life subscales, particularly for patients with vitreous hemorrhage, suggesting vitrectomy effectively enhances visual quality of life for those with diabetic retinopathy.